The pharmacy day | A question to investigate
A pilot should earn the next decision
A pilot can generate activity, screenshots and enthusiastic feedback without answering whether anyone should continue paying for the change. A useful pharmacy evaluation begins with the investment or operating decision it is meant to support. That could be adding a service, changing a workflow or testing whether a proposed PHARMORIS capability has value beyond existing tools. The first task is to define what evidence would make the decision different.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Choose a problem with an accountable owner
Name the person who can act on the result and the constraint they face. A pharmacist may identify repeated work, while an owner controls staffing or expenditure. A commissioner may value a pathway outcome that the pharmacy cannot deliver alone. Bring those perspectives together before choosing measures. The evaluation should have a clear sponsor and operational lead, with professional responsibility preserved. An interested conversation is not a commissioned pilot, and a pilot is not a product endorsement.
Make the alternative credible
The comparator might be ordinary practice, an improved spreadsheet or an existing supplier function. Describe it fairly and include its true maintenance effort. A proposed tool should not win merely because the baseline was poorly explained. For an early feasibility test, the aim may be to show that an approach can fit the work at all. A later comparative study requires stronger methods. Keep those purposes separate so that a small first test is not marketed as proof of effectiveness.
Agree a minimum evidence set
Choose a small number of measures that connect directly to the decision: completion of a defined workflow, preparation effort, unresolved exceptions, staff acceptability and actual delivery cost. Write the denominator and observation period for each. Include a quality or professional safeguard selected by the responsible team. GPhC standards and any relevant service or quality-scheme requirements remain part of the operating context; the pilot does not replace them or confer an approval of its own (General Pharmaceutical Council, n.d.; NHSBSA, n.d.).
Write the decision rule before the result
Complete a one-page agreement: decision owner, problem, current alternative, proposed change, primary operational measure, quality safeguard, additional workload limit and stop condition. Add what happens after a positive, negative or inconclusive result. If nobody can explain which decision the evidence will change, refine the question before starting. This gives a potential customer or investor something assessable: a disciplined learning commitment with an economic purpose, rather than a pilot label attached to ordinary activity.
Write the decision rule before the result.
An investment case gets stronger when it explains the conditions for repetition. Make the next commitment depend on evidence.
A pharmacy and a prospective evaluation sponsor need to decide whether a proposed change deserves a bounded test. The owner, comparator and decision rule are not yet clear enough to justify a larger commitment.
Supports an investable boundary: suitable now, suitable after a defined dependency, unsuitable under present conditions or still unknown.
What would we need to understand?
- The specific operating change and decision owner
- Baseline service mix and professional cover
- Central and local implementation effort
- Site differences, non-participation and exceptions
Constructed decision example | No customer results are shown.
Protect the operating day and the information
Start with authorised aggregate information where that can answer the question. Set a limit on the additional work participants will undertake, and decide how exceptions or concerns will be raised. Any patient-level data, research involvement or system access requires a separately justified scope and appropriate arrangements before use. A public pilot page can explain the problem, evaluation question and intended outputs without revealing sensitive architecture, individual records or commercially confidential operating details.
Define both success and a responsible stop
Agree what would justify continuing, what would trigger redesign and what would end the evaluation. Include poor data quality, excessive staff burden and an inability to maintain professional safeguards. A promising result might justify a larger study rather than purchase; an inconclusive result may be useful if it identifies a missing condition. The output should report adverse or inconvenient findings alongside encouraging ones, with uncertainty visible and no automatic extrapolation to a wider pharmacy network.
Make the commercial proposition explicit
A proposed engagement needs a defined scope, deliverable, responsibilities, timetable and fee if applicable. Distinguish the cost of an assessment from any future licence, implementation or ongoing support. If the evaluation depends on a capability still under development, say what can currently be demonstrated and what remains to be built. Neither a grant nor a local demonstration proves buyer value. The pilot should help establish whether the problem is important enough and the proposed response useful enough for a further commitment.
NEUVIOR Data Analysis
A source.
A question.
A clearer decision.
Useful intelligence keeps its evidence attached.
Our public analysis connects a defined question with named sources, reporting periods and methods. Each source below shows the work available today and the access still needed.
Published-data analysis, research hypotheses and evidence studies are distinct kinds of work. Their meaning should remain clear as the programme grows.
NHS Business Services Authority | Annual
Prescription Cost Analysis
How does activity differ from ingredient-cost concentration?
Analysis availableNHS Business Services Authority | Monthly
English Prescribing Dataset with SNOMED Code
Which product and organisational patterns merit a closer investigation?
Metadata retrievedMedicines and Healthcare products Regulatory Agency | Event-driven; monthly roundup also published
Medicines and device safety communications
Which official communication should a responsible team read next?
Snapshot retrievedNHS Business Services Authority and NHS England | Weekly
Dictionary of medicines and devices
Can the same product identity be followed consistently across sources?
Access reviewBring a decision worth resolving
The best invitation is specific: here is the recurring problem, here is what we currently do, here is who could change it and here is the evidence we need. We can then discuss whether a bounded PHARMORIS evaluation is appropriate and feasible. The ambition is to produce a result a pharmacy owner, professional team or investor can assess clearly, including when the result says the idea needs to change before it deserves more time or money.
Sources and scope
GPhC | Registered pharmacy standards | NHSBSA | Pharmacy Quality Scheme
General Pharmaceutical Council (n.d.) Registered pharmacy standards. Available at: https://inspections.pharmacyregulation.org/standards (Accessed: 14 October 2026).
NHSBSA (n.d.) Pharmacy Quality Scheme. Available at: https://www.nhsbsa.nhs.uk/provider-assurance-pharmaceutical-services/pharmacy-quality-scheme-pqs (Accessed: 14 October 2026).
Another useful angle.
- Independent pharmacy | Make the next service earn its place
A practical decision framework for independent owners comparing service demand, capacity, costs and cash before expanding.
- Online pharmacies | Design for continuity beyond the order
Explore a professional evaluation of remote pharmacy handovers, failed contacts, delivery exceptions and continuity.
- New Medicine Service | Make follow-up workable
A practical evaluation of NMS follow-up scheduling, contact effort and continuity without promising clinical outcomes.